Amgen builds Otezla’s psoriasis label as rival BMS looms large

[cafead]

via Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb’s much-touted rival deucravacitinib, which could make its debut next year.

article source